尿激酶型纤溶酶原激活剂及其受体在髓母细胞瘤中的表达研究

Expression of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in medulloblastomas

目的 研究尿激酶型纤溶酶原激活剂（uPA）及受体（uPAR）在髓母细胞瘤中的表达及临床意义。方法 应用免疫组化LSAB法检测50例髓母细胞瘤中uPA及uPAR的表达,结合临床随访,使用Cox回归统计分析。结果 uPA及uPAR染色定位于肿瘤细胞和血管内皮细胞。Cox回归分析显示uPA及uPAR是影响生存时间的预后因子,它们与预后存在一定的负相关关系。结论 uPA及uPAR可作为预测髓母细胞瘤患者预后的客观指标。

Objective To study expression and clinical significance of urokinase-type plasminogen activator (uPA) and urokinase-type plasminogen activator receptor (uPAR) in medulloblastomas. Methods Expressions of uPA and uPAR were examined in 50 patients with medulloblastomas using LSAB immunohistochemical technique, and follow-up survey was conducted with Cox regression analysis. Results The staining outcome demonstrated that uPA and uPAR were localized on tumor cells and endothelial cells. Cox regression analysis showed that uPA and uPAR were prognostic factors affecting survival and they had negative correlation with the prognosis. Conclusion The data suggest that uPA and uPAR play a role in predicting prognosis of medulloblastomas.